Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Adamson

Showing results (101-110 of 176) with videos related to

Pageof 18
Sort By:
Cancer Chemotherapy and Pharmacology|December 20, 2011
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studySteven G DuBois, Suzanne Shusterman, Joel M Reid, et al.
Pediatric Blood & Cancer|January 6, 2010
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium studyLars M Wagner, John P Perentesis, Joel M Reid, et al.
Cancer|January 27, 2009
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyLisa M McGregor, Sheri L Spunt, Wayne L Furman, et al.
Journal of Clinical Pharmacology|October 22, 2005
Drug utilization in the pediatric intensive care unit: monitoring prescribing trends and establishing prioritization of pharmacotherapeutic evaluation of critically ill childrenAthena F Zuppa, Peter C Adamson, John T Mondick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.
Pediatric Blood & Cancer|September 23, 2010
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology GroupBrigitte C Widemann, Robert J Arceci, Nalini Jayaprakash, et al.
Pediatric Blood & Cancer|July 1, 2010
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group studyRani E George, Jill M Lahti, Peter C Adamson, et al.
Pediatric Blood & Cancer|July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyOrren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of the National Cancer Institute|April 5, 2017
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH TrialCarl E Allen, Theodore W Laetsch, Rajen Mody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium StudyRegina I Jakacki, Marta Hamilton, Richard J Gilbertson, et al.
Pageof 18

Showing results (101-110 of 176) with videos related to

Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|December 20, 2011
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studySteven G DuBois, Suzanne Shusterman, Joel M Reid, et al.
Pediatric Blood & Cancer|January 6, 2010
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium studyLars M Wagner, John P Perentesis, Joel M Reid, et al.
Cancer|January 27, 2009
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyLisa M McGregor, Sheri L Spunt, Wayne L Furman, et al.
Journal of Clinical Pharmacology|October 22, 2005
Drug utilization in the pediatric intensive care unit: monitoring prescribing trends and establishing prioritization of pharmacotherapeutic evaluation of critically ill childrenAthena F Zuppa, Peter C Adamson, John T Mondick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2012
Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium studyYael P Mossé, Emily Lipsitz, Elizabeth Fox, et al.
Pediatric Blood & Cancer|September 23, 2010
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology GroupBrigitte C Widemann, Robert J Arceci, Nalini Jayaprakash, et al.
Pediatric Blood & Cancer|July 1, 2010
Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group studyRani E George, Jill M Lahti, Peter C Adamson, et al.
Pediatric Blood & Cancer|July 27, 2010
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group studyOrren Beaty, Stacey Berg, Susan Blaney, et al.
Journal of the National Cancer Institute|April 5, 2017
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH TrialCarl E Allen, Theodore W Laetsch, Rajen Mody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium StudyRegina I Jakacki, Marta Hamilton, Richard J Gilbertson, et al.
Pageof 18